politics
Moderna’s mRNA flu shot to get FDA review
Key takeaways
- Link copied by Joseph Choi and Nathaniel Weixel - 05/22/26 6:52 PM ET Link copied Presented by Coalition to Strengthen America s Healthcare{beacon}
- After some initial back-and-forth, Moderna s candidate for a m RNA flu vaccine will get a review by a Food and Drug Administration (FDA) advisory panel next month.
- The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna s MFLUSIVA flu vaccine, according to a Federal Register notice published Thursday.
Why this matters: political developments that affect policy direction and public trust.
Link copied by Joseph Choi and Nathaniel Weixel - 05/22/26 6:52 PM ET Link copied Presented by Coalition to Strengthen America s Healthcare{beacon}
After some initial back-and-forth, Moderna s candidate for a m RNA flu vaccine will get a review by a Food and Drug Administration (FDA) advisory panel next month.
The panel will meet June 18 to discuss and make recommendations on the safety and effectiveness of Moderna s MFLUSIVA flu vaccine, according to a Federal Register notice published Thursday. The FDA is set to make a decision by Aug. 5, in time for the next flu season.
Article preview — originally published by The Hill. Full story at the source.
Read full story on The Hill →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from The Hill alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop